Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest TNF inhibitor Stories

2012-11-13 08:33:42

BRUSSELS, Nov. 13, 2012 /PRNewswire/ -- UCB announced extensive results from the Phase 3 study - RAPID(TM)-axSpA - at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington D.C., U.S. RAPID(TM)-axSpA enrolled patients with active axial spondyloarthritis (axSpA), including patients with ankylosing spondylitis (AS) and axSpA without radiographic evidence of AS (non-radiographic axSpA [nr-axSpA]). The study showed that...

2012-11-12 08:27:53

WASHINGTON, Nov. 12, 2012 /PRNewswire/ -- New Phase 3 findings from a Janssen Research & Development, LLC (Janssen)-sponsored study showed treatment with the investigational intravenous (I.V.) therapy golimumab, a tumor necrosis factor (TNF) inhibitor, significantly inhibited radiographic progression in patients with active moderate to severe rheumatoid arthritis (RA) despite treatment with methotrexate. Analysis of study patients' X-rays showed significant inhibition of the progression...

2012-11-12 08:27:42

WASHINGTON, Nov. 12, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today new findings from PSUMMIT II, a Phase 3 investigational study that showed patients with active psoriatic arthritis, including those previously treated with one to five tumor necrosis factor (TNF) inhibitors, receiving the interleukin (IL)-12/23 inhibitor STELARA(®) (ustekinumab) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patients...

2012-11-12 08:26:51

ABBOTT PARK, Ill., Nov. 12, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the first long-term patient-reported health outcomes data from an open-label analysis of the ongoing, Phase 3 ABILITY-1 trial of HUMIRA(®) (adalimumab). The study evaluated improvements in physical function and health-related quality of life (HRQOL) after 52 weeks in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). These results are being presented at the American College of...

2012-11-09 08:27:23

ATLANTA and BRUSSELS, Nov. 9, 2012 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on immunology treatment and research, is proud to announce new data on two compounds in its immunology portfolio for a broad range of rheumatic conditions at the American College of Rheumatology's (ACR) 2012 Annual Scientific Meeting in Washington, D.C., November 10-14. The data include posters and oral presentations on Cimzia® (certolizumab pegol) for the treatment of moderate to severe...

2012-10-25 07:31:45

MOUNTAIN VIEW, Calif., Oct. 25, 2012 /PRNewswire/ -- Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic class available to psoriatic arthritis (PsA) patients in need of additional therapy beyond standard of care. This represents a significant unmet need for alternative therapies for TNF inhibitor refractory patients. New analysis from Frost & Sullivan's (http://www.healthcare.frost.com) United States Market for Psoriatic Arthritis Pharmacotherapy research finds...

2012-10-22 11:26:08

ABBOTT PARK, Ill., Oct. 22, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA® (adalimumab) ULTRA 1 and ULTRA 2 studies. Adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to certain other medications and were treated with HUMIRA were evaluated for symptom improvement for up to three years. In this long-term analysis,...

2012-10-22 07:29:39

LAS VEGAS, Oct. 22, 2012 /PRNewswire/ -- New Phase 3 study findings showed significantly more patients with moderately to severely active ulcerative colitis (UC) who responded to induction therapy with subcutaneously administered SIMPONI(®) (golimumab) maintained clinical response through week 54, the primary endpoint of the study, compared with patients receiving placebo. Investigators will report clinical response, clinical remission and mucosal healing results through one year from...

2012-10-18 07:25:44

MOUNTAIN VIEW, Calif., Oct. 18, 2012 /PRNewswire/ -- The availability of tumor necrosis factor (TNF) inhibitors has greatly improved the pharmacological management of rheumatoid arthritis (RA). Both patients and physicians are familiar with TNF inhibitors due to their long history; however, their many limitations such as high cost, potential side effects, and injection requirement have created a need for alternative therapies. This need, along with a potentially large patient pool,...

2012-10-17 15:22:50

SPRING HOUSE, Pa., Oct. 17, 2012 /PRNewswire/ -- Findings from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial evaluating the efficacy and safety of STELARA(®) (ustekinumab) in the treatment of moderate to severe Crohn's disease appeared today in The New England Journal of Medicine. The results showed that among patients who had previously failed or were intolerant to at least one tumor necrosis factor (TNF) antagonist, a significantly greater proportion...